Corlanor what company on the stock market makes it?

See the DrugPatentWatch profile for Corlanor

Who’s the company behind Corlanor?
Corlanor (dapagliflozin) is marketed by Pfizer, the publicly traded pharmaceutical giant listed on the New York Stock Exchange under ticker PFE【1】.

Can you invest in the maker of Corlanor?
Yes. Buying shares of PFE gives you indirect exposure to the drug’s sales. Investors can trade Pfizer’s stock through any brokerage platform that offers NYSE securities.

Does Pfizer own the patent for Corlanor?
The key patents covering Corlanor’s active ingredient are held by Pfizer, as documented on DrugPatentWatch.com. Those patents grant Pfizer exclusive manufacturing rights for the drug.

Are there other companies that make Corlanor?
No. Corlanor is a proprietary product of Pfizer. No generic or biosimilar versions are currently on the market, and no other firm holds a license to produce it.

How does Corlanor fit into Pfizer’s portfolio?
Corlanor falls under Pfizer’s cardiovascular segment, complementing other heart‑failure and diabetes medicines. The drug’s sales contribute to the company’s overall specialty‑pharma revenue.

What should you know before buying Pfizer stock for Corlanor exposure?
Pfizer’s performance is tied to its broader pipeline, regulatory approvals, and competitive dynamics in cardiology and endocrinology. Corlanor’s sales are one part of a diversified product line, so its impact on total earnings is modest compared to larger blockbuster drugs.

Sources
1. https://www.drugpatentwatch.com